What Next for PTC Therapeutics, Inc. (PTCT) Stock After Reaching 52-Week High?

March 20, 2018 - By Winifred Garcia

Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported.
Qs Invsts Lc holds 229,338 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Advent Mngmt De holds 10,000 shares or 0% of its portfolio. Jane Street Group Incorporated Ltd Liability invested in 78,768 shares or 0.01% of the stock. Prelude Cap Ltd Limited Liability Company has 181,379 shares. Citigroup holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 40,468 shares. Intl Gp has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Legal General Grp Public Ltd reported 9,414 shares. Goldman Sachs Group Inc holds 0% or 282,450 shares. Pub Employees Retirement Association Of Colorado stated it has 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). State Board Of Administration Of Florida Retirement Systems has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Bancorp Of New York Mellon stated it has 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Gotham Asset Management Ltd Liability holds 0.01% or 19,796 shares. Proshare Advsrs Lc invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Manufacturers Life Insur The invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT).

Since January 3, 2018, it had 0 insider buys, and 4 selling transactions for $61,523 activity. 412 shares valued at $7,280 were sold by Utter Christine Marie on Wednesday, January 3. Almstead Neil Gregory also sold $1,361 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares.

The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) hit a new 52-week high and has $34.90 target or 9.00 % above today’s $32.02 share price. The 7 months bullish chart indicates low risk for the $1.34 billion company. The 1-year high was reported on Mar, 20 by Barchart.com. If the $34.90 price target is reached, the company will be worth $120.42M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 6.31% or $1.9 during the last trading session, reaching $32.02. About 437,393 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since March 20, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on May, 14. They expect $-0.35 EPS, up 58.82 % or $0.50 from last year’s $-0.85 per share. After $0.03 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1,266.67 % negative EPS growth.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics has $135 highest and $6 lowest target. $37.80’s average target is 18.05% above currents $32.02 stock price. PTC Therapeutics had 38 analyst reports since July 31, 2015 according to SRatingsIntel. Jefferies initiated PTC Therapeutics, Inc. (NASDAQ:PTCT) rating on Friday, October 23. Jefferies has “Hold” rating and $26 target. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, August 9. The firm earned “Outperform” rating on Friday, October 16 by Oppenheimer. On Tuesday, February 23 the stock rating was downgraded by JP Morgan to “Neutral”. On Wednesday, February 24 the stock rating was maintained by Wedbush with “Outperform”. On Monday, October 9 the stock rating was downgraded by JP Morgan to “Underweight”. Jefferies upgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) on Wednesday, February 24 to “Hold” rating. Barclays Capital maintained the stock with “Equal-Weight” rating in Wednesday, March 7 report. The firm earned “Sell” rating on Thursday, October 26 by Bank of America. The firm has “Hold” rating by RBC Capital Markets given on Wednesday, October 25.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $1.34 billion. The company's lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.